Stock Financial Ratios, Dividends, Split History

INSG / Inseego Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)115.86
Enterprise Value ($M)99.69
Book Value ($M)-49.18
Book Value / Share-0.83
Price / Book-2.36
NCAV ($M)-142.41
NCAV / Share-2.40
Price / NCAV-0.81
Share Statistics
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 58,644,559
Common Shares Outstanding 58,830,682
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.42
Return on Assets (ROA)-0.29
Return on Equity (ROE)2.58
Balance Sheet (mrq) ($M)
Quick Ratio0.68
Current Ratio0.93
Income Statement (mra) ($M)
Sales Revenue Goods Net160,986,000.00
Io Tand Mobile Solutions Net Revenues0.00
Sales Revenue Services Net58,311,000.00
Enterprise Saa S Solutions Net Revenues0.00
Operating Income-22.21
Net Income-45.84
Earnings Per Share Basic-0.78
Earnings Per Share Basic And Diluted-0.78
Earnings Per Share Diluted-0.78
Cash Flow Statement (mra) ($M)
Cash From Operations-14.64
Cash from Investing-4.38
Cash from Financing-4.38
Identifiers and Descriptors
Central Index Key (CIK)1022652

Split History

Stock splits are used by Inseego Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

SA Interview: Learning The Lerna Capital Way - How They Help Companies Create Value

2018-07-15 seekingalpha
Why some company-level shorts have turned into macro shorts, how Lerna Capital helps companies unlock value and a defense of David Einhorn are topics discussed. (10-0)

Go Time For An Inseego Turnaround

2018-06-22 seekingalpha
Disclaimer: This material is furnished by Lerna Capital LLC or affiliates (collectively “Lerna”). This material is for information purposes only and is not an offer or a solicitation to subscribe for or purchase the securities mentioned. This material is not intended to provide a sufficient basis on which to make an investment decision. All market and commercial data in this thesis are not warranted as to completeness or accuracy. (8-1)

SHU Portfolio: There Is A Bright Light At The End Of The Inseego Tunnel

2018-05-16 seekingalpha
But the restructuring has paid off already and the company already has several businesses growing at a significant pace. (1-0)

Inseego's (INSG) CEO Dan Mondor on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Hello, and welcome to Inseego Corp.’s First Quarter 2018 Financial Results Conference Call. Please note that today’s event is being recorded. All participants are in a listen-only mode. [Operator Instructions] After today’s presentation there will be an opportunity for analysts to ask questions. (3-3)

Inseego Is Making Solid Progress, Now For The Next Act

2018-03-12 seekingalpha
The company is in Act 1 of its turnaround plan and we can say, so far, so good as the company even turned in a small operating profit already. (1-1)

CUSIP: 66987M604